Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 351, Issue 3, pp 274–281 | Cite as

Characterization of bradykinin receptors mediating catecholamine release in PC12 cells

  • A. Dendorfer
  • P. Dominiak
Original Article

Abstract

The rat pheochromocytoma cell line PC12, which is a widely used model for analyzing stimulus-secretion coupling, was investigated for the effects of kinins on catecholamine release. Subtypes of kinin receptors were characterized using the B1 agonist desArg9-bradykinin, the B2 agonist bradykinin and the B2 antagonists [Thi5,8, D-Phe7]-bradykinin, D-Arg[Hyp3, D-Tic7, Oic8]-bradykinin (HOE 890307) and D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin (HOE 140). The effectiveness of acute and chronic exposure to angiotensin I converting enzyme inhibitors as well as pretreatment of the cells with bacterial lipopolysaccharides in modulating B1 or B2 receptor systems was also tested.

Bradykinin stimulated noradrenaline release from PC12 cells at low concentrations (EC50 = 1 nM), maximally inducing a release of 43.7% of the cellular content within 15 min. In comparison with acetylcholine and K+-induced depolarization, bradykinin was the most effective stimulus. DesArg9-bradykinin was only effective at very high concentrations (> 30 μM). Like in other neuronal cells, the B2-specific partial antagonist [Thi5,8, D-Phe7]-bradykinin acted as a low-affinity agonist without any antagonistic effects. The B2 antagonists HOE 890307 and HOE 140 exerted no agonistic effects and concentration-dependently inhibited bradykinin-induced noradrenaline release, showing competitive antagonism with Ki values of 1.38 nM and 0.66 nM, respectively. Only at the highest concentration used (1 μM), HOE 140 did depress the maximal response to bradykinin. HOE 890307 also abolished the effects of desArg9-bradykinin and [Thi5,8, D-Phe7]-bradykinin. Acute or chronic inhibition of the angiotensin I converting enzyme or application of lipopolysaccharides, which all can lead to induction of the B1 receptor subtype in vivo, did not alter the secretory response of PC12 cells to either bradykinin (0.1 and 30 nM) or desArg9-bradykinin (1 μM).

In conclusion, noradrenaline release from PC12 cells is stimulated via B2, but not B1, receptors. Despite the fact that the receptor system is highly susceptible to stimulation by low-affinity ligands, HOE 890307 and HOE 140 are pure antagonists, with only high concentrations of HOE 140 (> 1 μM) showing a non-competitive type of inhibition. Induction of B1 receptors which could stimulate noradrenaline release could not be demonstrated in this model. The possible role of bradykinin in modulating sympathetic neurotransmission during inhibition of angiotensin I converting enzyme is discussed.

Key words

Bradykinin desArg9-bradykinin PC12 cells Kinin receptors Catecholamines HOE 890307 HOE 140 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barabé J, Babiuk C, Regoli D (1982) Binding of 3H-des-Arg-BK to rabbit anterior mesenteric vein. Can J Physiol Pharmacol 60:1551–1555Google Scholar
  2. Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. Nature (Lond) 341:197–205Google Scholar
  3. Braas KM, Manning DC, Perry DC, Snyder SH (1988) Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors. Br J Pharmacol 94:3–5Google Scholar
  4. Brasch H, Sieroslawski L, Dominiak P (1993) Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype I receptors. Hypertension 22:699–704Google Scholar
  5. Bueb JL, Mousli M, Landry Y, Regoli D (1993) Structure-activity studies of bradykinin's analogues on rat mast cell histamine release. Peptides 14:685–689Google Scholar
  6. Clementi E, Scheer H, Zacchetti D, Fasolato C, Pozzan T, Meldolesi J (1992) Receptor-activated Ca2+ influx. J Biol Chem 4:2164–2172Google Scholar
  7. DeBlois D, Bouthillier J, Marceau F (1991) Pulse exposure to protein synthesis inhibitors enhances vascular responses to desArg9-bradykinin: possible role of interleukin-1. Br J Pharmacol 103:1057–1066Google Scholar
  8. Dendorfer A, Wellhöner P, Dominiak P (1994) De novo synthesis and release of kininogen by PC12 cells. J Hypertens 12 [Suppl 3]:S161Google Scholar
  9. Dominiak P, Blöchl A (1991) Does converting enzyme inhibition change the neuronal and extraneuronal uptake of catecholamines? Basic Res Cardiol 86 [Suppl 3]:149–156Google Scholar
  10. Dominiak P, Elfrath A, Türck D (1987) Effects of chronic treatment with ramipril, a new ACE blocking agent, on presynaptic sympathetic nervous system of SHR. Clin Exp Hypertens 9(A):369–373Google Scholar
  11. Dominiak P, Simon M, Blöchl A, Brenner P (1992) Changes in peripheral sympathetic outflow of pithed spontaneously hypertensive rats after bradykinin and desArg-bradykinin infusions: Influence of converting-enzyme inhibition. J Cardiovasc Pharmacol 20 [Suppl 9]:S35-S38Google Scholar
  12. Dray A, Bettaney J, Forster P, Perkins MN (1988) Activation of a bradykinin receptor in peripheral nerve and spinal cord in the neonatal rat in vitro. Br J Pharmacol 95:1008–1010Google Scholar
  13. Fasolato C, Pandiella A, Meldolesi J, Pozzan T (1988) Generation of inositol phosphates, cytosolic Ca2+, and ionic fluxes in PC12 cells treated with bradykinin. J Biol Chem 263(33):17350–17359Google Scholar
  14. Feldberg W, Lewis GP (1964) The action of peptides on the adrenal medulla. Release of adrenaline by bradykinin and angiotensin. J Physiol (Lond) 171:98–108Google Scholar
  15. Greene LA, Rein G (1977) Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res 129:247–263Google Scholar
  16. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424–2428Google Scholar
  17. Grohovaz F, Zacchetti D, Clementi E, Lorenzon P, Meldolesi J, Fumagalli G (1991) [Ca2+]i imaging in PC12 cells: Multiple response patterns to receptor activation reveal new aspects of transmembrane signaling. J Cell Biol 113:1341–1350Google Scholar
  18. Hall JM (1992) Bradykinin receptors: Pharmacological properties and biological roles. Pharmac Ther 56:131–190Google Scholar
  19. Horwitz J (1991) Bradykinin activates a phospholipase D that hydrolyzes phosphatidylcholine in PC12 cells. J Neurochem 56:509–517Google Scholar
  20. Kim K-T, Westhead EW (1989) Cellular responses to Ca2+ from extracellular and intracellular sources are different as shown by simultaneous measurements of cytosolic Ca2+ and secretion from bovine chromaffin cells. Proc Natl Acad Sci USA 86:9881–9885Google Scholar
  21. Kuo Y-JJ, Keeton TK (1991) Captopril increases norepinephrine spillover rate in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 258:223–231Google Scholar
  22. Lembeck F, Griesbacher T, Eckhardt M, Henke S, Breipohl G, Knolle J (1991) New, long-acting, potent bradykinin antagonists. Br J Pharmacol 102:297–304Google Scholar
  23. Llona I, Vavrek R, Stewart J, Huidobro-Toro JP (1987) Identification of pre- and postsynaptic bradykinin receptor sites in the vas deferens: evidence for different structural prerequisites. J Pharmacol Exp Ther 241:608–614Google Scholar
  24. Llona I, Galleguillos X, Belmar J, Huidobro-Toro JP (1991) Bradykinin modulates the release of noradrenaline from vas deferens nerve terminals. Life Sci 48:2585–2592Google Scholar
  25. Lowry OH, Rosebrought NH, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  26. Majewski H, Hedler L, Schurr C, Starke K (1984) Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II. J Cardiovasc Pharmacol 6:888–896Google Scholar
  27. Mulinari R, Benetos A, Gavras I, Gavras H (1988) Vascular and sympathoadrenal responses to bradykinin and a bradykinin analogue. Hypertension 11:754–757Google Scholar
  28. Nolly H, Saed G, Carretero OA, Scicli G, Scicli AG (1993) Adrenal kallikrein. Hypertension 21:911–915Google Scholar
  29. Nwator IAA, Whalley ET (1989) Angiotensin converting enzyme inhibitors and expression of des-Arg9-BK (kinin B1) receptors in vivo. Eur J Pharmacol 160:125–132Google Scholar
  30. Owen PJ, Plevin R, Boarder MR (1989) Characterization of bradykinin-stimulated release of noradrenaline from cultured bovine chromaffin cells. J Pharmacol Exp Ther 248:1231–1236Google Scholar
  31. Pozzan T, Gatti G, Dozio N, Vicentini LM, Meldolesi J (1984) Ca2+-dependent and -independent release of neurotransmitters from PC12 cells: A role for protein kinase C activation? J Cell Biol 99:628–638Google Scholar
  32. Ransom JT, Cherwinski HM, Dunne JF, Sharif NA (1991) Flow cytometric analysis of internal calcium mobilization via a B2-bradykinin receptor on a subclone of PC-12 cells. J Neurochem 56:983–989Google Scholar
  33. Regoli D, Jukic D, Gobeil F, Rhaleb N-E (1993) Receptors for bradykinin and related kinins: a critical analysis. Can J Physiol Pharmacol 71:556–567Google Scholar
  34. Ritchi AK (1979) Catecholamine secretion in a rat pheochromocytoma cell line: Two pathways for calcium entry. J Physiol 286:541–561Google Scholar
  35. Schild HO (1947) pA, a new scale for the measurement of drug antagonism. Br J Pharmacol 2:189–206Google Scholar
  36. Schömig E, Schönfeld CL, Halbrügge T, Graefe KH, Trendelenburg U (1990) The heterogeneity of the neuronal distribution of exogenous noradrenaline in the rat vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol 342:160–170Google Scholar
  37. Starke K, Peskar BA, Schumacher KA, Taube JD (1977) Bradykinin and postganglionic sympathetic transmission. Naunyn-Schmiedeberg's Arch Pharmacol 299:23–32Google Scholar
  38. Staszewska-Barczak J, Vane JR (1967) The release of catecholamines from the adrenal medulla by peptides. Br J Pharmac Chemother 30:655–667Google Scholar
  39. Vavrek RJ, Stewart JM (1985) Competitive antagonists of bradykinin. Peptides 6:161–164Google Scholar
  40. Weiss C, Atlas D (1990) The bradykinin receptor — a putative receptor-operated channel in PC 12 cells: studies of neurotransmitter release and inositol phosphate accumulation. Brain Res 543:102–110Google Scholar
  41. Wilson SK, Lynch DR, Snyder SH (1987) Angiotensin-converting enzyme labeled with [3H]captopril. J Clin Invest 80:841–851Google Scholar
  42. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, Konig W, Knolle J, Schölkens BA (1991) HOE 140, a new potent and long-acting bradykinin antagonist: in vivo studies. Br J Pharmacol 102:774–777Google Scholar
  43. Zhu J, Hexum T (1992) Characterization of cocaine-sensitive dopamine uptake in PC12 cells. Neurochem Int 21:521–526Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • A. Dendorfer
    • 1
  • P. Dominiak
    • 1
  1. 1.Insitute of PharmacologyMedical University of LübeckLübeckGermany

Personalised recommendations